Sort   by:  
 Page size 
ProteomicsProteomic comparison study between cancer cachexia muscle of C26 and CT mice
Background Loss of skeletal muscle mass in advanced cancer is recognized as an independent predictor of mortality. Mechanisms involved in this wasting process and parameters for early diagnosis are still lacking. As skeletal muscle is considered as a secretory organ, the aim of this present experime...
ORGANISM(S): Mus musculus (Mouse) 
2020-10-28 | PXD016474 | Pride
Cancer Biomarkers C26 mice Cachexia Muscle Atrophy 
ProteomicsFibrosis associated changes detected in the proteome of surface epithelium overlying Crohn’s Disease Strictures
Background and aims: Intestinal fibrosis is a common complication of Crohn’s disease (CD). It is characterised by an excessive accumulation of fibroblasts differentiating into activated myofibroblasts secreting excessive extracellular matrix. The potential role of the intestinal epithelium in this f...
ORGANISM(S): Homo sapiens (Human) 
2022-04-04 | PXD022214 | Pride
Inflammatory bowel disease Label free proteomics Surface epithelium Fibrostenosis Ileum 
ProteomicsDiscovery of potential early colorectal cancer biomarker
Differential analysis of proteomes originated from early lesion of colorectal cancer and colon control tissue using FFPE-FASPTM and Label free analysis using 2DnanoUPLC separation before analysis on a qTOF synapt HDMS G2 using ion mobility as supplementary separation dimension
ORGANISM(S): Homo sapiens (Human) 
2017-03-28 | PXD005735 | Pride
Pt2nm Early stage Ffpe-fasp Human colorectal cancer Pt1nm Label free 
ProteomicsMarked increased production of acute phase reactants by skeletal muscle during cancer cachexia
Background Loss of skeletal muscle mass in cancer cachexia is recognized as an independent predictor of mortality. Mechanisms involved in this wasting process and parameters for early diagnosis are not yet clearly defined. As skeletal muscle is considered as a secretory organ, the aim of this prese...
ORGANISM(S): Mus Musculus 
2021-01-24 | PXD019433 | panorama
ProteomicsDiscovery of biomarker candidates associated with the risk of short- and long-term relapse after infliximab withdrawal in Crohn’s patients: a proteomics-based study
Objective: A subset of Crohn’s disease (CD) patients experiences long-term remission after infliximab withdrawal. Biomarkers are needed to identify those patients. Design: New biomarkers of relapse were searched in the baseline serum of CD patients stopping infliximab when they were under combined t...
ORGANISM(S): Homo Sapiens 
2020-11-02 | PXD019434 | panorama
ProteomicsExternal validation of serum biomarkers predicting short-term and mid/long-term relapse in Crohn’s disease patients stopping infliximab
Background and aims: In Crohn’s disease (CD) patients on combination therapy (infliximab and immunosuppressant) and stopping infliximab (STORI cohort), the risk of short-term (<6 months) and mid/long-term relapse (>6 months) was associated with specific blood protein profiles. Our aim was to test th...
ORGANISM(S): Homo Sapiens 
PXD051233 | panorama
Sort   by:  
 Page size